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Table 2 - Sleeve lobectomy versus pneumonectomy for lung cancer
Sleeve lobectomy Pneumonectomy
No of patients 300(1976-2005) 1,046 (1980-2000)
Mean age 61.2 ± 11 years 60.7 ± 9.4 years
Operative mortality 2.7 % (8 / 300) 5.3 % (55 / 1,046)
Overall 5 year survival 54 % 31 %
Locoregional recurrences 16 % 35 %
During that period, sleeve resection was always done whenever techni-
cally possible while pneumonectomy was reserved for lesions that 
could not be removed by a bronchoplastic procedure. While lesions in 
the hilum of the right upper lobe were the commonest indication for 
sleeve resection, all lobes of either lung could be involved with tumors 
amenable to some form of lung-sparing bronchoplastic procedure. All 
patients included in the analysis were staged by nodal sampling and 
according to the 1997 revised TNM nomenclature.
There were 8 operative deaths out of 300 patients who underwent 
sleeve resection (2.7 %) and 55 operative deaths out of the 1,046 
patients who underwent pneumonectomy (5.3 %, p < 0.05) and most 
causes of death in either group were related to respiratory events. Of 
note, four patients (1.3 %) had anastomotic complications after sleeve 
resection but none of these complications lead to mortality.
Follow-up was complete for the entire cohort and the overall 5-year 
survival was signiﬁcantly better after sleeve resection (54 %) than after 
pneumonectomy (31 %, p < 0.0001) (see Table 2). For patients with 
N1 disease, there was also a signiﬁcant difference in survival favoring 
sleeve lobectomy (sleeve resection (N : 72) : 50 %; pneumonectomy 
(N : 361) : 34 %; p 0.015). When recurrences occurred, the site of ﬁrst 
recurrence was locoregional in 16 % after sleeve resection and in 35 % 
of patients after pneumonectomy.
In summary, this analysis demonstrates that sleeve resection is an effec-
tive procedure for patients who could tolerate a pneumonectomy but in 
whom the surgeon judges that a complete resection is possible through 
a bronchoplastic procedure with conservation of pulmonary function. 
As a general statement, sleeve lobectomy should be considered in any 
case of lung cancer which can be completely resected by this technique.
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The indication for a sleeve resection for lung cancer is well established: 
a tumor arising at the origin of a lobar bronchus but not inﬁltrating as 
far as to require pneumonectomy. In addition, a sleeve resection may 
be indicated when N1 nodes inﬁltrate the bronchus from the outside, 
as is often the case in the left upper lobe tumors requiring a combined 
reconstruction of the bronchus and the pulmonary artery. From a func-
tional point of view, sleeve lobectomy is strictly indicated in patients 
who cannot withstand pneumonectomy, but recent experiences have 
shown that the advantages of sparing lung parenchyma are evident also 
in patients without cardio-pulmonary impairment. Oncologically, the 
primary goal is in every case the complete resection of the tumor with 
free resection margins. 
When analyzing survival data reported in literature in the last 15 years, 
most of the studies show similar or better results for parenchymal 
sparing resections if compared with pneumonectomy. Moreover, in the 
analysis of 5-year survival according to stage (Table-1) and nodal sta-
tus, sleeve lobectomy results in higher survival rates for stages I, II and 
III, although the survival advantage in stage III appears to be limited. In 
a recent report (Ludwig’05), sleeve lobectomy results a statistically sig-
niﬁcant favourable prognostic factor for long-term survival with a sur-
vival advantage in patients with N0, N1 and N2 disease. However, this 
prognostic advantage for stage III-N2 patients is not always conﬁrmed, 
and there are other studies reporting a more evident adverse effect on 
survival for patients with N2 involvement who have undergone sleeve 
lobectomy. Therefore the role of parenchymal sparing operations in pa-
tients with N2 disease still remains not completely deﬁned (Fadel’02).
Table 1
Author (year) Stage I patients
Stage II 
patients
Stage III 
patients
Stage I  
5-yr 
survival 
(%)
Stage II 
5-yr 
survival 
(%)
Stage III  
5-yr  
survival 
(%)
Sleeve Lobectomy
Van Schil (‘91) 61 57 - 59 21 -
Gaissert (‘96) 29 31 12 42 53 43
Icard (‘99) 32 57 16 60 30 27
Tronc (‘00) 83 73 26 63 48 8
Fadel (‘02) 54 47 36 55 62 21
Mezzetti (‘02) 34 32 17 61 39 9
Terzi (‘02) 48 52 50 60 32 22
Deslauriers (‘04) 83 72 29 66 50 19
Kim (‘05) 14 18 15 88 52 8
Ludwig (‘05) 31 41 44 57 40 22
Pneumonectomy
Gaissert (‘96) 9 25 21 - 43 -
Mizushima (‘97) 8 15 84 58 42 13
Deslauririers (‘04) 164 361 471 50 34 22
Kim (‘05) 28 11 10 75 36 38
Ludwig (‘05) 31 52 111 45 42 13
These results justify the increasing use of parenchymal sparing proce-
dures for lung cancer also in patients with good cardio-pulmonary func-
tion, as observed in the last years. 
Postoperative morbidity and mortality data reveal overall better results 
for patients undergoing sleeve lobectomy with respect to pneumonec-
tomy (Table-2). Looking at literature data, when morbidity is evaluated 
according to the type of complication, pneumonectomy patients appear 
to experience a higher rate of cardiac complications, while sleeve lo-
bectomy patients show increased pulmonary and airway complications 
incidence.
The incidence of microscopic inﬁltration of the bronchial margins has 
strong signiﬁcance when analyzing the anastomotic complication and 
local recurrence rate. Authors (Kim’05) who have observed a signiﬁ-
cantly higher incidence of anastomotic leak in their sleeve lobectomy 
series, report an increased rate of positive margins on frozen section. In 
our experience (since 1989) of 192 bronchial sleeve resections and 100 
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resections and reconstructions of the pulmonary artery no increased 
overall and pulmonary morbidity and mortality rate has been observed. 
The preservation of lung parenchyma has been indicated by some 
authors as the possible cause of a theoretical increased risk for loco-
regional recurrence after sleeve lobectomy. However, although in 
some experiences (Fadel’02) a higher local recurrence rate is reported 
for sleeve resection with advancing nodal status (N2), the few studies 
(Fadel’02,Terzi’02,Kim’05) analyzing risk factors for recurrence, show 
that the tumor stage and the nodal status are the only negative predic-
tive factors, rather than the type of operation performed. 
Table 2
Author (year) Complications (%)
Postoperative 
mortality (%)
Local recurrence 
(%)
Distant  
recurrence (%)
Sleeve Lobectomy
Gaissert (‘96) 11 4 14 -
Icard (‘99) 44 2.8 17 24
Okada (‘00) 13 8 -
Tronc (‘00) 16 1.6 22 11
Fadel (‘02) 16 2.9 15 11
Mezzetti (‘02) 10.8 3.6 20 -
Terzi (‘02) 14.5 12 5 18
Kim (‘05) 74.9 6.1 22 22
Ludwig (‘05) 38 4.3 - -
Pneumonectomy
Gaissert (‘96) 16 9 - -
Okada (‘99) 22 2 10 -
Deslauriers (‘04) - 5.3 35 -
Kim (‘05) 44 4.1 6 20
Ludwig (‘05) 26 4.6 - -
Postoperative quality of life has been advocated as one of the stron-
gest indicators that should inﬂuence the decision to perform a sleeve 
lobectomy rather than a pneumonectomy. A number of studies indicate 
that lung parenchyma sparing improves postoperative quality of life 
determining a greater cardio-pulmonary reserve, less pulmonary edema 
and less right ventricular dysfunction due to a lower pulmonary vascu-
lar resistance (Terzi’02,Martin-Ucar’02).
Special concern has been expressed by many thoracic surgeons when 
considering broncho-vascular reconstructive procedures after induction 
therapy, due to the signiﬁcantly higher risk of perioperative complica-
tions and mortality. Although only a few authors (Rendina’97,Ohta’03
,Stamatis’02) use sleeve resection routinely after neoadjuvant therapy, 
it has been proven in our experience (2,3), that also complex parenchy-
mal sparing operations can be performed after oncological treatment 
without increased morbidity and mortality rates observing long-term 
results comparable to those of the standard procedures (5-year survival: 
31%; local recurrence rate:15%). 
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Lobectomy with hilar and mediastinal lymph node dissection is the 
standard of care for patients with early stage non-small cell lung cancer 
(NSCLC). Wedge resection and segmentectomy, a parenchyma sparing 
anatomic resection, are limited resection options. The choice between 
lobectomy and limited resection is made by an assessment of the condi-
tion of the patient and associated risk of the operation, and the biology 
of the cancer. Perioperative mortality of lobectomy is 2-5%, but is 1% 
or less for limited resection. The main advantage of lobectomy is that it 
removes additional lung parenchyma and intralobar lymphatics which 
may contain micrometastatic tumor cells. The Lung Cancer Study 
Group (LCSG) randomized controlled trial of lobectomy versus open 
wedge resection for T1N0 NSCLC in 1995 found a marked increased 
risk of local recurrence, and a trend towards poorer survival that was 
not statistically signiﬁcant. Yet limited resection of lung cancer is a use-
ful option in select populations.
Limited resection is appropriate for patients who have insufﬁcient 
pulmonary reserve to tolerate lobectomy. Limited resection is also 
appropriate for patients with multifocal bronchioloalveolar carcinoma 
(BAC), who beneﬁt from complete resection of nodules, but whose 
entire normal lungs are at risk for disease recurrence. Additional patient 
populations may have equivalent outcomes with limited resection com-
pared with lobectomy. First, one observational study reported equiva-
lent survival among elderly patients with lobectomy or limited resec-
tion. Elderly patients, especially current and former smokers, are at risk 
for non-lung cancer related death, and the small oncologic beneﬁt of 
lobectomy may be outweighed by the upfront increased perioperative 
risk of lobectomy compared with limited resection in this population. 
Tumors smaller than 2cm and tumors associated with ground glass 
opacities (GGO) are being increasingly detected on computed tomogra-
phy. Observational studies suggest that limited resection for very small 
NSCLC, especially when associated with at least 50% GGO are associ-
ated with long term survival of greater than 90%, equivalent to survival 
of similar patients undergoing lobectomy. The LCSG trial had few 
patients with tumors smaller than 2cm. An ongoing randomized con-
trolled study in Japan and a planned trial in the US have been designed 
to further investigate optimal treatment of NSCLC smaller than 2cm. 
Finally, genomic analysis holds promise to guide therapy based on the 
biology of individual patient tumors. The future of lung cancer treat-
ment will involve treatment decisions, including extent or resection and 
beneﬁt of additional systemic therapies based on preoperative sampling 
of tumor genetic material. 
